HC Wainwright reissued their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $1.00 price target on the stock.
Separately, Bank of America lowered their price target on Lyell Immunopharma from $9.00 to $6.00 and set a buy rating for the company in a research note on Thursday, June 27th.
View Our Latest Analysis on LYEL
Lyell Immunopharma Price Performance
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. On average, equities research analysts anticipate that Lyell Immunopharma will post -0.85 earnings per share for the current year.
Institutional Investors Weigh In On Lyell Immunopharma
Large investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at approximately $31,000. RPO LLC acquired a new stake in Lyell Immunopharma in the 4th quarter worth approximately $38,000. Simplicity Wealth LLC acquired a new stake in Lyell Immunopharma in the 1st quarter worth approximately $58,000. Dimensional Fund Advisors LP lifted its holdings in Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after purchasing an additional 26,635 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma in the 1st quarter worth approximately $64,000. Institutional investors own 66.05% of the company’s stock.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Further Reading
- Five stocks we like better than Lyell Immunopharma
- What is the Hang Seng index?
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- 3 Healthcare Dividend Stocks to Buy
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- What is a Stock Market Index and How Do You Use Them?
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.